Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13362446 | 1.00 | AKT1 (0.45) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL13362515 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL8535643 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL2010648 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL8521627 | 0.99 | AKT1 (0.47) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL2008168 | 0.97 | AKT1 (0.45) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL6465596 | 0.96 | AKT1 (0.48) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL7141387 | 0.96 | SYNJ2 (0.45) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL6465598 | 0.96 | AKT1 (0.48) | AKT1CETPSYNJ2KDM4EABL1 | |
| SCHEMBL15821144 | 0.96 | AKT1 (0.48) | AKT1CETPSYNJ2KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046543-A1 | METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF APOPTOSIS INDUCING LIGANDS IN CANCER TREATMENT | The United States of America, as represented by the Secretary, Department of Healthe and Human (US) | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046543-A1 | METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF APOPTOSIS INDUCING LIGANDS IN CANCER TREATMENT | MCL1, BAD, TPD52L2 | AKT1 2166/4885CETP 2611/4885SYNJ2 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.